Business Description
![Panbela Therapeutics Inc Panbela Therapeutics Inc logo](https://static.gurufocus.com/logos/0C0000APEW.png?14)
Panbela Therapeutics Inc
NAICS : 325412
SIC : 2834
ISIN : US86664M2061
Share Class Description:
PBLA: Ordinary SharesDescription
Panbela Therapeutics Inc is a clinical-stage biopharmaceutical company developing disruptive therapeutics for the treatment of patients with urgent unmet medical needs. The Company's pipeline assets are ivospemin (SBP-101), FlynpoviTM (eflornithine (CPP-1X) and sulindac), and eflornithine (CPP-1X), which provide a multi-targeted approach to reset dysregulated biology present in many types of diseases such as cancer and autoimmunity.
Financial Strength
4/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Cash-To-Debt | 0.06 | |||||
Equity-to-Asset | -0.3 | |||||
Debt-to-Equity | -1.32 | |||||
Debt-to-EBITDA | -0.15 | |||||
Piotroski F-Score | 3/9 | |||||
WACC vs ROIC |
Growth Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year EBITDA Growth Rate | 76.6 | |||||
3-Year EPS without NRI Growth Rate | 25 | |||||
3-Year FCF Growth Rate | 74.4 |
Momentum Rank
2/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
5-Day RSI | 57.64 | |||||
9-Day RSI | 52.19 | |||||
14-Day RSI | 49.02 | |||||
6-1 Month Momentum % | -97.81 | |||||
12-1 Month Momentum % | -99.03 |
Liquidity Ratio
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
Current Ratio | 0.17 | |||||
Quick Ratio | 0.17 | |||||
Cash Ratio | 0.02 |
Dividend & Buy Back
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
3-Year Average Share Buyback Ratio | -962.7 | |||||
Shareholder Yield % | -735.5 |
Profitability Rank
1/10
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
ROA % | -197.57 | |||||
ROIC % | -276.54 | |||||
ROCE % | -806.5 |
GF Value Rank
Name | Current | Vs Industry | Vs History | |||
---|---|---|---|---|---|---|
EV-to-EBIT | -0.22 | |||||
EV-to-Forward-EBIT | -0.21 | |||||
EV-to-EBITDA | -0.22 | |||||
EV-to-Forward-EBITDA | -0.21 | |||||
EV-to-FCF | -0.24 | |||||
Earnings Yield (Greenblatt) % | -454.55 | |||||
FCF Yield % | -1281.67 |
Historical Operating Revenue by Business Segment
Historical Operating Revenue by Geographic Region
Guru Trades
See DetailsInsider Trades
See DetailsGurus Latest Trades with OTCPK:PBLA
You need a Premium membership or above to view this section.
Take a 7-Day Free Trial
No Available Data
Peter Lynch Chart
Performance
Dividend
Log
Bar
Annualized Return % Â
Total Annual Return % Â
Panbela Therapeutics Inc Executives
DetailsGF Value
Analyst Estimate
Key Statistics
Name | Value | ||
---|---|---|---|
Revenue (TTM) (Mil $) | |||
EPS (TTM) ($) | -228.567 | ||
Beta | 1.54 | ||
Volatility % | 132.62 | ||
14-Day RSI | 49.02 | ||
14-Day ATR ($) | 0.054568 | ||
20-Day SMA ($) | 0.394279 | ||
12-1 Month Momentum % | -99.03 | ||
52-Week Range ($) | 0.35 - 61.4 | ||
Shares Outstanding (Mil) | 4.85 |
Piotroski F-Score Details
Year:
Component | Result | ||
---|---|---|---|
Piotroski F-Score | 3 | ||
Positive ROA | |||
Positive CFROA | |||
Higher ROA yoy | |||
CFROA > ROA | |||
Lower Leverage yoy | |||
Higher Current Ratio yoy | |||
Less Shares Outstanding yoy | |||
Higher Gross Margin yoy | |||
Higher Asset Turnover yoy |
Panbela Therapeutics Inc Filings
Filing Date | Document Date | Form | ||
---|---|---|---|---|
No Filing Data |
Panbela Therapeutics Inc Stock Events
Event | Date | Price($) | ||
---|---|---|---|---|
No Event Data |
Panbela Therapeutics Inc Frequently Asked Questions
What is Panbela Therapeutics Inc(PBLA)'s stock price today?
The current price of PBLA is $0.40. The 52 week high of PBLA is $61.40 and 52 week low is $0.35.
When is next earnings date of Panbela Therapeutics Inc(PBLA)?
The next earnings date of Panbela Therapeutics Inc(PBLA) is 2024-08-09 Est..
Does Panbela Therapeutics Inc(PBLA) pay dividends? If so, how much?
Panbela Therapeutics Inc(PBLA) does not pay dividend.
Press Release
Subject | Date | |||
---|---|---|---|---|
No Press Release |